Navigation Links
Infinata's BioPharm Clinical™ to Present Session on Improving Investigator Selection at CHI’s Summit for Clinical Operations (SCOPE) on February 6 in Miami, FL
Date:2/1/2013

Norwood, MA (PRWEB) February 01, 2013

On February 6 at 7:45am, BioPharm Clinical™ will present an educational session on improving study feasibility and investigator selection by using patient pool demographic data at CHI’s Summit for Clinical Operations (SCOPE) in Miami, FL. BioPharm Clinical is also co-sponsoring the summit. Topics to be covered in the presentation include the growing importance of international investigators and how to more closely examine U.S. investigators as they become increasingly active in multiple studies that strain their available patients and resources.

Data analytics in BioPharm Clinical and surveys conducted by the company show…

  • The percent of started studies with U.S. sites only has decreased from 54% to 29% since 2000
  • 53% of investigators are located outside of the U.S.
  • Clinical operations professionals surveyed on investigator selection report that their primary concerns are commitment/availability (56%) and patient pool size (41%), far outweighing every other factor offered in the survey
  • 40% of all U.S. investigators who started a new study in the past three years started more than one
  • The average number of active studies per U.S. investigator has increased approximately 50% (from 1.43 to 2.13) since 2000

“These trends demonstrate how critical it is for clinical operations teams to receive the tools and support they need in order to reliably assess study feasibility and to select investigators who will meet enrollment goals,” said session presenter Sean Melville, Business Development Director of BioPharm Clinical. “At SCOPE, we will show how leading global pharmaceutical companies and clinical research organizations (CROs) are leveraging new streams of data including patient pool demographics – such as those available in our +Precision™ database - to make more informed and efficient t
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. Sutro Biopharma Appoints Edward C. Albini as Chief Financial Officer
2. Array BioPharma To Report Financial Results For The Second Quarter Of Fiscal 2013 On February 4, 2013
3. BioPharm Systems to Host Webinar on an Add-On Solution for Oracle Clinical
4. BioPharm Systems to Host Webinar on Self-service Account Management for Oracle Clinical, Remote Data Capture, and Thesaurus Management System
5. Array BioPharma Provides Updates On Clinical Data At The 2012 American Society Of Hematology Meeting
6. TransCelerate BioPharma Inc. Appoints Dalvir Gill as Chief Executive Officer
7. Array BioPharma Announces Exercise And Closing Of Underwriters Over-Allotment Option
8. Gallus BioPharmaceuticals Announces Appointment of Senior Baxter Executive as Chief Commercial Officer
9. PDL BioPharma to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
10. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
11. John A. Orwin Joins Array BioPharma Board Of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 29, 2015  Pfenex Inc. (NYSE ... financial results will be released on Thursday, August 13, ... Eastern Time, Pfenex management will host a conference call ... update.  A press release outlining the financial results and ... call. Please call 1-866-376-8058 (US) or 1-412-542-4131 ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - Aeterna Zentaris ... announced it has selected an optimized Erk inhibitor ... in the development of a new class of ... pathway represents a prime target for therapeutic intervention ... activities and survival benefits for B-Raf and Mek ...
(Date:7/29/2015)... ... 2015 , ... Costello served as Lead Levee Design Engineering Manager for a ... Texas area from future storm surge flooding, such as occurred in Hurricane Ike in ... alternatives for providing protection, Costello also balanced socio-economic and environmental needs and ...
(Date:7/28/2015)... , July 29, 2015 A ... acquiring, rapidly developing and commercialising innovative medicines ...   Highly experienced management team; blue chip ...   Mereo BioPharma Group Ltd ("Mereo"), a ... $119m ( c. £76.5m), gross, from blue chip institutional ...
Breaking Biology Technology:Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3Preventing Storm Surge Flooding in Houston 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11
... Renovis, Inc.,(Nasdaq: RNVS ), today announced that Glass ... ISS/Risk Metrics in recommending that Renovis,stockholders vote "FOR" the ... the Special Stockholders Meeting scheduled for May,1, 2008. In ... will be,converted into the right to receive the equivalent ...
... measurement helps physicians guide therapy for ... cardiometabolic risk patients, ... apoB are now recognized as valid, accurate and recommended,methods of ... risk